JANSSEN RESEARCH & DEVELOPMENT, LLC

Targeted Drug Combination Induces Remission in CLL Patients, Improving Survival and Quality of Life

- A phase III clinical trial, FLAIR, demonstrated that a combination of venetoclax and ibrutinib is more effective than chemotherapy for chronic lymphocytic leukemia (CLL). - The targeted drug combination significantly increased the time patients lived without cancer progression and improved overall survival, with over 95% in remission after three years. - The treatment was well-tolerated, resulting in fewer side effects and a better quality of life, especially for older patients who may not tolerate chemotherapy. - One patient, William Bennett, remains cancer-free nearly six years after starting the trial, highlighting the potential for long-term remission with this approach.